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Abstract 
Background: Alcohol use in HIV infected patients is associated with risky sexual behaviour, poor adherence to 
Highly Active Antiretroviral Therapy, treatment failure and increased physiologic harm. The objectives of the study 
were to pilot the outcome assessments to be used in the trial proper, assess the feasibility of delivery of a brief MI/CBT 
intervention compared to an WHO mhGAP intervention for problematic alcohol use in PLWH in Zimbabwe, and pilot 
the effectiveness (on alcohol use, functionality and CD4 count) of these interventions at 3 months in a randomised 
controlled trial design.
Methods: An intervention for HIV infected patients with problematic alcohol use, developed through adaptation of 
existing evidence based psychological treatments, was assessed for its feasibility at a tertiary HIV care clinic in Zimba-
bwe. Registered general nurses, using a manualised protocol, delivered the intervention. Forty patients were recruited 
and randomised to receive either an MI/CBT intervention or the WHO mhGAP Intervention Guide for AUDs (n = 20 
patients per group).
Results: Out of 40 participants enrolled, 31 were successfully followed up for 3 months with a loss to follow-up rate 
of 23%. There was a statistically significant decrease in AUDIT score over time in both groups (p < 0.001), however no 
statistically significant group difference with a mean difference of 0.80, standard error of 2.07 and p = 0.70. For the 
CD4 count, the median and interquartile ranges at baseline for MI/CBT and WHO mhGAP IG groups were 218 (274) 
and 484 (211.50), respectively. At follow-up, median and interquartile ranges for the CD4 count for MI/CBT and WHO 
mhGAP IG groups were 390 (280) and 567 (378), respectively, indicative of improvement in immunological parameters 
in both arms.
Conclusion: The findings from this pilot study suggests that a brief MI/CBT delivered by Registered General Nurses 
for problematic alcohol use is feasible in this population but will require the implementation of additional measures 
to improve retention. However, mechanisms to improve retention need special attention.
Trial registration Pan African Clinical Trial Registry, current PACTR201509001211149
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Background
Alcohol and illicit drug use can interfere with the success 
of HIV treatment programs and should be specifically 
targeted at patients in HIV care settings [52]. A US study 
found that alcohol use in HIV positive individuals was 
associated with higher rates of medical complications 
and poorer HIV treatment outcomes, including reduced 
viral load suppression [9]. Studies have shown that peo-
ple living with HIV (PLWH) drink twice as much as the 
general population, with increased mortality and physi-
ological injury occurring at relatively low levels of alcohol 
use [21]. Studies from Nigeria, Brazil and Ethiopia have 
documented prevalence rates of problematic alcohol use 
in PLWH in the range of 14% to 32% [15, 19, 51]. There 
is no data on problematic alcohol use in HIV infected 
persons in Zimbabwe Although the burden of disease 
is high with 1.6 million Zimbabweans living with HIV 
and 800,000 on antiretroviral treatment [38]. With this 
burden of HIV and with high levels of alcohol intake, a 
significant proportion of the population may have prob-
lematic alcohol use requiring intervention that is cultur-
ally acceptable.
A systematic review for determinants of adherence to 
HAART found alcohol use to be an obstacle to adherence 
[24]. Alcohol use is associated with Hepatitis B and C co-
infection and in PLWH liver malfunction may affect the 
metabolism of antiretroviral drugs [46]. Aside from the 
problems of non-adherence in PLWH, poor treatment 
outcomes may result from the physiological effects of 
alcohol. There is evidence that interventions for alcohol 
use can lead to the reduction in alcohol consumption in 
the general population [9]. Studies have also shown that 
psychological interventions in PLWH can improve medi-
cation adherence even when these interventions have no 
effect on alcohol use [48, 54]. Motivational interviewing, 
cognitive behaviour therapy, problem solving techniques, 
contingency management and twelve-step facilitation are 
some of the psychological interventions that have evi-
dence of effectiveness [11].
In developed countries where, highly trained special-
ists usually deliver psychological therapies, it has been 
shown that they can lead to a change in drinking behav-
iour. There have only been a few studies in low resource 
settings [42]. A Kenyan study by Papas et al. [39], using 
an adapted cognitive behavioural therapy intervention, 
showed improvement in alcohol use outcomes in HIV 
infected individuals [39]. Another study from Uganda 
found that counselling and motivational interviewing, 
had more beneficial effects in women than in men with 
hazardous alcohol use [54]. Another study undertaken 
in South Africa that utilised group therapy also docu-
mented a reduction in the amount of alcohol consumed 
by drinking participants [59]. A qualitative study to 
explore the acceptability of an alcohol use intervention by 
Kekwaletswe et al. found that participants were willing to 
engage in an alcohol-focused motivational interviewing 
treatment [27].
Although motivational interviewing is effective in 
motivating individuals to reduce alcohol consump-
tion, its effects have been shown to fade over time and 
booster sessions have been recommended [41]. Further, 
some studies have combined motivational interviewing 
with cognitive behavioural therapy in participants with 
comorbidities, such as depression and anxiety [47]. Zim-
babwe has commenced rollout of the WHO mh-GAP IG 
for mental health interventions [31]. This has followed 
a call by the WHO for wide dissemination of the WHO 
mh GAP IG in an endeavour to close the treatment gap 
for mental, neurological and substance use disorders. 
Moreover, Counselling for Alcohol Problems (CAP), a 
large study in India used WHO mh-GAP IG as a compar-
ison in their mental health trials [36]. Use of the WHO 
mh-GAP IG in PLWH with problematic alcohol use, if 
shown to be effective, can further reduce the treatment 
gap for mental disorder comorbidities in this vulnerable 
population.
While these studies have demonstrated benefits, larger 
sample studies are required [39, 54]. Further, varia-
tion in selection criteria and in the type of interventions 
across studies makes comparability challenging [17]. For 
example, patients with more dependence may require 
a larger dose of an intervention and may also benefit 
from stepped up care, yet most studies focus on a sin-
gle intervention [18]. To this end, there are studies being 
conducted to assess the effectiveness of psychological 
therapies in HIV in addressing mental health and drink-
ing problems [29, 40]. Limited access to skilled staff may 
impede the successful implementation of interventions 
for the management of HIV and comorbid alcohol use 
[43] and there have been calls to use task sharing as a way 
to address the staff and skills shortage [14, 28, 42]. Given 
that highly skilled personnel have traditionally delivered 
psychological therapies it is essential to find innovative 
ways of bridging this gap. HIV care providers, such as 
nurses, could be trained in the safe and effective delivery 
of treatments for problematic alcohol use in PLWH and 
in so doing improve medication adherence and HIV out-
comes [7].
Feasibility studies are necessary to assess (i) contextual 
factors that may need to be incorporated into treatment 
protocols, (ii) barriers and facilitators to the provision 
of interventions, (iii) service-related factors and (iv) the 
availability of resources to deliver the interventions as 
this can potentially influence outcomes [6]. This study 
sought to obtain baseline data on problematic alcohol 
use using the AUDIT in a nurse driven HIV care setting. 
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In addition, we sought to assess the utility of the AUDIT 
and obtain pilot data on the effectiveness of an interven-
tion for problematic alcohol use, as delivered by regis-
tered general nurses.
Ethics
The Health Research Ethics Committee of the Stellen-
bosch University (SI14/10/222), the Medical Research 
Council of Zimbabwe (A/1936) and the Harare Hospital 
Ethics Committee approved this study.
Aim
To pilot the outcome assessments to be used in the trial 
proper, assess the feasibility of delivery of a brief MI/CBT 
intervention compared to an WHO mhGAP interven-
tion for problematic alcohol use in PLWH in Zimbabwe, 
and pilot the effectiveness (on alcohol use, functionality, 
quality of life and CD4 count) of these interventions at 
3 months in a randomised controlled trial design.
Methods
Recruitment
Recruitment of participants took place from the 8th to 
the 28th January 2016. The final assessment of outcomes 
was completed on the 30th of April 2016. The study set-
ting was a tertiary HIV clinic run by nurses and medical 
doctors. Research assistants recruited participants dur-
ing their routine clinic attendance. Informed consent was 
obtained from willing participants. Baseline data were 
collected on all participants and the interventions were 
delivered in February and March 2016. A computer-gen-
erated randomization schedule was used to assign par-
ticipants to the two interventions. As a retention strategy, 
we noted the contact details of participants and their 
significant others and reminded participants of their 
appointments on the day prior to their study visits.
Setting
Harare Central Hospital HIV care clinic which is a ter-
tiary level clinic. Patients were referred from acute medi-
cal wards and primary care clinics in the city of Harare 
and Zimbabwe as a whole.
Inclusion and exclusion criteria
Participants were adults aged 18  years and older. In 
order to be included, female participants had to score 
at least 6 and male participants at least 7 [44], respec-
tively, on the Alcohol Use Disorders Identification Test 
(AUDIT), scores that are indicative of problematic drink-
ing (www.who.int/subst ance_abuse /publi catio ns/audit /
en) [3]. There is evidence that low alcohol consumption 
in HIV positive individuals is associated with increased 
harm than in HIV negative adults [10]. Participants were 
screened for cognitive impairment with the International 
HIV Dementia Scale (IHDS) with those by scoring 10 or 
less excluded. A score of 11 and below indicated cogni-
tive impairment. Mental illness was assessed with the 
Substance Abuse Mental Illness Symptom Screener 
(SAMISS) [55]. Positive responses to questions 8-16 are 
suggestive of mental illness while questions 1–7 are sug-
gestive of alcohol and other substance use problems. The 
Drug Use Disorders Identification Test (DUDIT) assesses 
other substance use with positive cut-points of 2 or more 
for females and 6 or more for males [5]. Participants had 
to be in receipt of HIV treatment at the clinic and receiv-
ing followed-up care for at least 3 months.
Nurse training
Ten registered general nurses were invited to participate. 
Training included the use of PowerPoint presentations, 
role-play, quizzes and assignments. Training was pro-
vided both in a classroom setting and on-site. Both inter-
ventions were manualised and 5 nurses each were trained 
in these interventions. The trainers included two psy-
chiatrists, a nurse practitioner and a clinical psychologist. 
The training was conducted over 2 days with the first day 
covering Good Clinical Practice and ethical principles for 
both groups of nurses. However, groups were separated 
on Day 2 of the training with each group receiving train-
ing in either MI/CBT or the WHO mh-GAP IG.
Quality assurance
Consent was requested and obtained from the nurses 
to audio-record the training and this formed the basis 
of supervision whereby the recordings were collectively 
reviewed and feedback provided in order to facilitate the 
acquisition of a similar level of skill among the nurses. 
Ten percent of the sessions that were administered and 
audiotaped were reviewed with the nurses and feedback 
was provided during supervision visits. The 7 sessions 
that were audio taped were reviewed at the 4 supervision 
sessions that were held during the study. The supervi-
sion visits were held on days and times when the clinic 
was closed to patients for medication collection. Where 
inconsistencies were noted, further training was pro-
vided, both in individual and group supervision format. 
Client evaluation and satisfaction cards were reviewed 
with each nurse, and where concerns were identified, 
they were discussed and resolved.
MI/CBT intervention
The MI/CBT intervention comprised a combination of 
motivational enhancement and cognitive-behavioural 
techniques and was an adaptation of these evidence-
based therapies for problematic alcohol use [45, 50]. 
Motivational interviewing is a therapy developed by 
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Miller and Rollnick [33] to treat patients with problem-
atic alcohol use. It can also be used for other problem-
atic behaviours. Patients with unhealthy alcohol use can 
change their drinking patterns when sufficiently moti-
vated through counselling that emphasizes empathic lis-
tening, avoiding arguments, rolling with resistance, and 
self-efficacy. Cognitive behavioural therapy (CBT) is a 
treatment based on the premise that certain behaviours 
are the result of faulty thinking. Drinking behaviour is 
associated with certain thinking patterns that result in 
cravings that can be addressed by CBT. Drinking can also 
be avoided if the patient has certain drink refusal skills 
that can be developed through CBT.
The intervention comprised 4 sessions, with each ses-
sion delivered in two parts as shown in Table  1. The 
duration of these sessions ranged from 30  min to 1 h. 
Table 1 shows the content [33] and duration of sessions. 
The motivational enhancement therapy themes included 
providing personal feedback on alcohol use, ‘change talk’ 
themes, and readiness to change the ‘ruler’. The cogni-
tive therapy elements encompassed setting goals, dealing 
with cravings and cues, faulty thinking patterns, dealing 
with stresses, and developing ‘drink refusal’ skills. Prob-
lem solving skills were also included in the intervention. 
All of the intervention sessions were audiotaped and 
reviewed with the intervention staff to facilitate uniform-
ity in the delivery of the intervention.
WHO mh-GAP IG: The World Health Organisation 
Mental Health Action Programme Intervention Guide 
(WHO mh-GAP IG) was the comparator [57]. The WHO 
mhGAP IG is designed for screening and management of 
common mental disorders, including problematic alcohol 
use, in primary care settings. It has been used as a control 
in other studies in low and middle-income countries [37]. 
The WHO mhGAP comprised an assessment of alcohol 
use on history, brief advice on harmful alcohol use, and 
referral for probable alcohol dependence. This interven-
tion was administered in a single session of 1 h by trained 
RGNs.
Assessment measures
At baseline and follow-up, the AUDIT, CD4 count, 
WHODAS 2.0 and the WHOQOL were administered. 
Table 1 Showing the MI/CBT intervention sessions
Session 1a, 30 min General life personal goal setting
Alcohol goals
General life personal goal setting
How alcohol use interfere with goals
Session 1b, 30 min Possible reasons why people drink
Establish you clients’ reasons for drink
Providing personal feedback moving the client towards change
Explaining the implications of drinking on treatment as indicated on CD4 and viral load
Meaning of improvement and the value of a functional life and quality of life
Drinking problems warning signs
Session 2a, 30 min Use MI to build rapport and develop readiness to change
Assess readiness to change (using readiness ruler)
Assess pros and cons of change (Decision-balance exercise)
Use MI to try and shift participant
Elicit a commitment to change
Session 2b, 30 min Brief explanation and principles of CBT
Explanation on what triggers, urges and cues are and how they lead to drinking
Discussion on how triggers arise and how they lead to use and effects
Managing thoughts about drink
Session 3a, 30 min Triggers
External
Internal
Drink refusals skills
Managing situations were drinking are unavoidable
Session 3a, 30 min Dealing with specific treatment issues like
 Receiving viral load and CD4 results, treatment problems, losing a spouse, employ-
ment threatened by illness, new illness related to the viral infection running out of 
medication
Session 4, 30 min Planning future direction
Life is back to normal: Do I drink?
Dealing with anger and criticism
Dealing with failure
Self-referral
Conclusion and planning the future
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Follow-up assessments were conducted for both group at 
3 months.
WHO AUDIT
The WHO AUDIT was used to screen participants and 
was also the primary outcome measure. The AUDIT is a 
10-item tool with a score range of 0 to 40 [8, 49]. In this 
study, scores of 6 and 7 for females and males, respec-
tively, were applied as cut-offs to identify patients with 
problematic drinking based on psychometric perfor-
mance of the AUDIT in previous studies [44]. Some stud-
ies have shown that HIV infected individuals require 
much less alcohol to get intoxicated and suffer physi-
ologic harm [26, 30]. Although the AUDIT has not been 
validated in Zimbabwe or among people living with HIV, 
it has been used in diverse population groups in South-
ern Africa and in Zimbabwe [12, 13]. The AUDIT has 
good psychometric properties with a Cronbach alpha of 
0.93 [95% CI (0.921–0.941)], specificity of 89.6% (95% 
CI 76.11–96.02 and sensitivity of 95.07% (95% CI 92.18–
96.97) against gold standard DSM-IV criteria, at a cut 
point of 6 [44]. The Cronbach alpha for the AUDIT in 
this study was 0.72.
Viral load and CD4
Trained general nurses collected blood for baseline viral 
loads and CD4 count. These assays were done at the hos-
pital laboratory. As a result of budgetary constraints, viral 
loads were not done at the 3-month assessment.
World Health Organisation Disability Assessment Schedule 
2.0 (WHODAS 2.0)
The WHODAS 2.0 is a tool developed by the WHO to 
assess the degree of disability and has been validated for 
a variety of health conditions ([22]; www.who.int/icidh /
whoda s/; www.who.int/menta l_healt h/media /en/613.
pdf) [56]. Although the WHODAS 2.0 has not been 
validated in Zimbabwe, it has been used in rural Ethio-
pia and was found to have good psychometric properties 
with an internal consistency ranging from very good to 
excellent (Cronbach’s alpha 0.82 to 0.98) [23]. The WHO-
DAS 2.0 has been validated for chronic diseases, such as 
HIV, and had good psychometric features [22]. The Cron-
bach alpha for the WHODAS 2.0 in this study was 0.91.
World Health Organisation Quality of Life HIV (WHOQOL HIV)
Quality of life was assessed using the WHO Quality of 
Life HIV (WHOQOL HIV) that has been validated for 
HIV elsewhere but not in Zimbabwe ([58, 25]; www.
who.int/menta l_healt h/media /en/613.pdf). The WHO-
QOL HIV has been validated in South Africa and Zambia 
and has good internal consistency with Cronbach alphas 
ranging from 0.889 to 0.933 in the Zambian study [35, 
53]. The Cronbach alpha for the WHOQOL HIV in this 
study was for 0.9 D for domain I, 0.59 for domain II, 0.92 
for domain III, and 0.49 for domain IV.
Data analysis
Data were analysed using SPSS. A mixed model ANOVA 
was used in the analysis. Primary and secondary out-
comes were measured at two time points at baseline 
and 3  months. The standardized mean difference of the 
AUDIT score was the measure of treatment effect. We 
summarized continuous variables using means (standard 
deviation) or medians (interquartile range) depending on 
the distribution, and categorical variables using counts 
(percentages). We used t-tests or Mann–Whitney U tests 
to compare means or medians between the two interven-
tion groups. We used Chi square tests or Fisher’s exact 
tests to test the association between study groups and 
other categorical variables. Alpha was set at = 0.05 and all 
tests were two sided.
Results
Recruitment, randomisation and retention
One hundred and two (102) patients were invited to par-
ticipate in the study. At screening, 33 scored less than 6 
on the AUDIT and 69 had scores at or above the cut-off. 
Eleven participants failed to meet the eligibility criteria 
and 18 declined to participate for reasons including mov-
ing away from Harare, work commitments and other rea-
sons. Forty participants were randomised to each group 
with no baseline differences between the groups, as 
shown in Table 3. At follow up, 4 participants were lost in 
the MI/CBT group and 5 in the mhGAP IG group. Three 
participants in the MI/CBT group and 4 in the mhGAP 
IG group relocated from Harare, while 1 participant in 
the MI/CBT group and 1 in the WHO mhGAP IG group 
were unable to secure time off from work (see Fig. 1).
Baseline characteristics
There were 17 female and 23 male participants in the 
study. The combined mean age was 39.5 years (SD = 9.59), 
with a mean age of 41.7 years (SD = 9.61) in the MI/CBT 
group and a mean age of 37.3  years (SD = 9.29) in the 
mhGAP IG group. Table 2 shows the socio-demographic 
characteristics of the sample. At study entry, 6 (15%) 
participants were on second line HAART and 34 (85%) 
had achieved viral suppression. Participants had been on 
HAART for 3.5 (SD1.2) years. The MI/CBT group had a 
significantly lower median CD4 count 201.5 (range of 85 
to 367) than the mhGAP group 390 (range of 200 to 400) 
(p = 0.03). Table 2 shows the sociodemographic features 
of the study population. The participants were predomi-
nantly male and more than 50% were married.
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Interventions
A total of 74 interventions sessions were administered 
with a median of 3.7 (1 to 4 sessions) sessions per par-
ticipant and 14.8 sessions per nurse. The duration of ses-
sions ranged from 30 to 55  min. In the mhGAP group, 
each nurse conducted a single session of the mhGAP at 
the first contact. A total of 20 sessions were administered 
to this group.
Outcomes
Alcohol use outcomes
There was no statistically significant difference in the 
AUDIT score at baseline (p = 0.57) between the groups 
as shown in Table 3. There was a statistically significant 
change in alcohol use in both groups over time (p < 0.001) 
as shown on Table 3. There was no difference in the mag-
nitude of change between the groups as shown the 95% 
CI in Fig. 2.
Screened >6 or 7
N=33
69 screened for eligibility 
for the trial 
IHDS (n=2)
DUDIT (n=6)
SAMISS (n=3)
Refused to take 
part (n=18)
Randomized 
(n=40)
Enrolment 
MI/CBT 
WHO mh 
GAP IG
N=20 N=20 
N=16 
(80%)
N=15 
(75%)
Follow-up 
Loss to 
follow-up 
5(25%)
Loss to 
follow-up 
4(20%)
102 screened with the AUDIT
Fig. 1 Study flow from screening to analysis
Table 2 Sociodemographic characteristics of  the  study 
population
MI/CBT mh GAP IG
Age 39.5 (4.3) 40.1 (3.8)
Gender
Female 9 (22.5%) 8 (20%)
Male 11 (27.5%) 12 (30%)
Marital status
Single 4 (10%) 3 (7.5%)
Married 12 (30%) 9 (22.5%)
Divorced 2 (5%) 4 (10%)
Widowed 3 (7.5%) 3 (7.5%)
Education
Years in school 9.5 (3.2) 10.1 (3.8)
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CD4
Due to the skewness in the data, we report medians and 
interquartile ranges. At follow-up, the median and inter-
quartile ranges for the MI/CBT and mhGAP IG groups 
were 390 (280) and 567 (378), respectively, indicative of 
improvement in immunological parameters although 
groups differences were not statistically significant as 
shown in Table 4.
Functioning and quality of life
Functioning and quality of life, as measured on the 
WHODAS 2.0 and the WHOQOL HIV, showed no 
change over time. Tables  5 and 6 show the treatments 
effects on the WHODAS 2.0 and WHOQOL HIV respec-
tively (Fig. 3).  
Discussion
The aim of this study was to pilot the outcome assess-
ments to be used in an adequately powered trial, assess 
the feasibility of delivery of a brief MI/CBT intervention 
compared to an WHO mhGAP intervention for prob-
lematic alcohol use in PLWH in Zimbabwe, and assess 
their preliminary effectiveness using a task-sharing 
model in a low resource setting with a huge HIV bur-
den. This sample of 40 HIV infected patients was drawn 
from an HIV care setting at a tertiary institution where 
participants received either blended motivational inter-
viewing/CBT or the WHO MH GAP IG. The retention 
rate was 77% at 3 months with no statistically significant 
Table 3 Change in  AUDIT scores between  MI/CBT 
and mhGAP at baseline and 3 months
There were however no statistically significant differences in AUDIT score 
between the arms at baseline (p = 0.57) and 3 months (p = 0.70)
Arms Mean baseline (SD) Mean 
at 3 months 
(SD)
p-value
mhGAP time 16.05 (7.21) 8.00 (5.79) < 0.001
MI/CBT over time 14.85 (7.78) 7.20 (5.07) < 0.001
group*time; LS Means
Current effect: F(1, 38)=.02107, p=.88535
Type III decomposition
Vertical bars denote 0.95 confidence intervals
 group
 control
 group
 intervention
pre post
time
2
4
6
8
10
12
14
16
18
20
22
TIDUA
a
b
a
b
Fig. 2 AUDIT for both arms. Both arms recorded significant falls in their AUDIT score
Table 4 Change in CD4 over the 3 month follow up period
MI/CBT median MI/CBT IQR MH GAP IG median MH GAP IQR p-value
CD4 count baseline 218 274 484 211.5 0.85
CD4 counts follow-up at 
3 months
390 280 567 378 0.56
Table 5 WHODAS scores for baseline and 3 months
Time-point MI/CBT mean (SD) MhGAP mean (SD) p-value
Baseline 13.7 (6.88) 15.5 (6.48) 0.91
3 months 13.4 (3.80) 13.3 (4.35) 0.77
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group difference. In both groups, drinking behaviour as 
assessed by AUDIT score and CD4 count improved after 
treatment.
Improvement in alcohol use in this population supports 
previous findings that participation in screening and 
exposure to alcohol counselling, and receipt of pamphlets 
or presentations can lead to reduction in alcohol use [11]. 
Studies have shown that in participants with early and 
low levels of alcohol use, low intensity interventions can 
lead to change in the level of alcohol use [2]. However, 
studies have also shown that patients who are dependent 
on alcohol do not change their drinking behaviour even 
with longer exposure to interventions [34]. Although 
we hypothesized that MI/CBT would result in a greater 
reduction in drinking than the mhGAP IG, this was 
not the case. Both interventions could be considered as 
‘active’ treatments. There has been a call to adapt and 
pilot treatments such as the WHO MH GAP IG, that are 
scalable in low- and middle- income countries [4].
Although there was change in the CD4 count in both 
groups, this was not statistically significant. Some studies 
have found no relationship between alcohol use and CD4 
count [1]. Functional capacity and quality of life did not 
show any change over time in the trial. The small sam-
ple size may have contributed to the lack of detection of a 
significant effect.
The loss to follow up was 23% despite retention efforts 
such as confirming appointments. Follow up assessments 
did not always coincide with scheduled clinic visits. Par-
ticipants at the clinic at which recruitment took place (a 
tertiary institution) are poorly adherent, have late stage 
disease and high rates of treatment failure. These are 
some of the characteristics of loss to follow up that were 
documented in a study in Ethiopia [32].
The study provides preliminary evidence that regis-
tered general nurses can be trained to offer a psycho-
logical intervention for dually diagnosed adults with HIV 
and unhealthy alcohol use. In Zimbabwe, nurses are at 
the forefront of provision of both curative and preven-
tive interventions in Zimbabwe. While task sharing an 
intervention for unhealthy alcohol use to nurses may be 
novel, nurses have been at the forefront of provision of 
HIV treatment with results that are comparable to those 
achieved by doctors [20].
This pilot study has a number of limitations. It is char-
acterized by a small sample and, as such, not adequately 
powered to demonstrate true treatment differences and 
hence prone to Type I error. The study recruited partici-
pants who had a known adherence, given that they were 
the inclusion criteria required the adherence clinic visits 
in the past 3 months. Further, the alcohol screening used 
the AUDIT, which is a self-report tool. As a result, has 
Table 6 WHOQOL (quality of  life) for  baseline 
and 3 months
Time-point MI/CBT mean (SD) MhGAP mean (SD) p-value
Baseline 71.65 (8.07) 69.63 (7.71) 0.78
3 months 73.33 (7.11) 72.94 (8.70) 0.81
group*time; LS Means
Current effect: F(1, 29)=.33917, p=.56481
Type III decomposition
Vertical bars denote 0.95 confidence intervals
 group
 control
 group
 intervention
pre post
time
250
300
350
400
450
500
550
600
650
700
750
4DC
Fig. 3 CD4 count for both arms. Group control represents the mh GAP IG arm and group intervention represents the MI/CBT arm
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social desirability bias [16]. The study was undertaken at 
a tertiary institution which serves as a referral centre for 
patients and not in primary or district care settings, thus 
morbidity present in the sample may not be reflective of 
HIV patients receiving care in the latter settings.
Conclusion
This study demonstrates the feasibility of administering 
the assessment tools employed here and delivering a brief 
MI/CBT intervention in HIV care clinics. The interven-
tions led to change in alcohol use. Further large samples 
studies that are adequately powered are needed. Strate-
gies to retain participants need to be carefully considered 
when integrating interventions for alcohol use treatment 
into usual care.
Abbreviations
AUDIT: Alcohol Use Disorders Identification Test; AUDs: Alcohol Use Disorders; 
CAP: Counselling for Alcohol Problems; CBT: Cognitive Behavioural Therapy; 
DSM IV: Diagnostic Statistical Manual Version 4; DUDIT: Drug Use Disorders 
Identification Test; HAART : Highly Active Antiretroviral Therapy; HIV: Human 
Immunodeficiency Virus; IHDS: International HIV Dementia Scale; MI/CBT: 
Motivational Interviewing/Cognitive Behavioural Therapy; MhGAP IG: Mental 
Health Gap Action Program Intervention Guide; PLWH: People Living With HIV; 
RGNs: Registered General Nurses; SAMISS: Substance Abuse Mental Illness 
Symptom Screener; SPSS: Statistical Package for Social Sciences; WHO: World 
Health Organisation; WHODAS: World Health Organisation Disability Assess-
ment Schedule; WHOQOL: World Health Organisation Quality of Life.
Authors’ contributions
MM and SS conceived and developed the study. MZ provided input on the 
statistical plan. RS critically reviewed statistical plan. DC provided input on 
the methods and revised the entire manuscript. MD and BMD helped with 
development of the intervention and controls and revised the manuscript. 
All authors critically revised the article for important intellectual content and 
all authors read and approved the final manuscript. All authors read and 
approved the final manuscript.
Author details
1 Department of Psychiatry, College of Health Sciences, Parirenyatwa Group 
of Hospitals, Avondale, Zimbabwe. 2 Psychiatric Hospital, Harare Central Hos-
pital, Southerton, Zimbabwe. 3 Global Health, Faculty of Medicine and Health 
Sciences, Stellenbosch University, Stellenbosch, South Africa. 4 Department 
of Community Medicine, College of Health Sciences, University of Zimbabwe, 
College of Health Sciences, Harare, Zimbabwe. 5 Department of Psychiatry, 
Faculty of Medicine and Health sciences, Stellenbosch University, Cape Town, 
South Africa. 
Acknowledgements
We would like to acknowledge Tafadzwa Chitsa for helping in the preparation 
of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
Not available.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study has received relevant institutional approvals from the Medical 
Research Council of Zimbabwe, Stellenbosch University Human Research 
Ethics Committee, and the Harare Hospital Ethics Committee. The Ministry of 
Health Permanent Secretary of Zimbabwe has also approved the study.
Funding
The South African Research Chairs Initiative in PTSD, funded by the Depart-
ment of Science and Technology and the National Research Foundation, 
supported the pilot study. The pilot study received funding from Partnership 
for Alcohol and AIDS Intervention Research (PAAIR), Stellenbosch University, 
Cape Town, South Africa.
Informed consent
Informed consent was be sought and obtained from participants. Participants 
were in- formed that their decision to participate in the study was voluntary 
and was not going to affect their care. Research staff who were not clinic 
employees or linked to participants’ medical care were asked for informed 
consent. The consent forms were translated and back-translated and adapted 
for cultural appropriateness and readability into Shona and Ndebele, the main 
local languages in Zimbabwe. Research personnel who had contact with par-
ticipants were asked to sign a confidentiality agreement, and received training 
and supervision on ethical conduct and confidentiality protection.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 1 June 2018   Accepted: 14 March 2019
References
 1. Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the 
impact of alcohol use disorders on HIV treatment outcomes, adherence 
to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 
2010;112(3):178–93. https ://doi.org/10.1016/j.druga lcdep .2010.06.014.
 2. Babor TF, Ritson EB, Hodgson RJ. Alcohol-related problems in the primary 
health care setting: a review of early intervention strategies. Br J Addict. 
1986;81(1):23–46.
 3. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. AUDIT: the alco-
hol use disorders identification test: guidelines for use in primary care. 
2nd ed. Geneva: World Health Organization; 2001.
 4. Baingana F, Al’absi M, Becker AE, Pringle B. Global research challenges 
and opportunities for mental health and substance-use disorders. Nature. 
2015;527(7578):S172–7. https ://doi.org/10.1038/natur e1603 2.
 5. Berman AH, Bergman H, Palmstierna T, Schlyter F. Evaluation of the Drug 
Use Disorders Identification Test (DUDIT) in criminal justice and detoxi-
fication settings and in a Swedish population sample. Eur Addict Res. 
2005;11(1):22–31. https ://doi.org/10.1159/00008 1413.
 6. Bernal G. Intervention development and cultural adaptation research 
with diverse families. Fam Process. 2006;45(2):143–51.
 7. Bernstein E, Bernstein J, Feldman J, Fernandez W, Hagan M, Mitchell P, 
Safi C, Woolard R, Mello M, Baird J, Lee C. An evidence based alcohol 
screening, brief intervention and referral to treatment (SBIRT) curriculum 
for emergency department (ED) providers improves skills and utilization. 
Subst Abus. 2007;28(4):79–92. https ://doi.org/10.1300/j465v 28n04 _01.
 8. Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification 
Test (AUDIT): validation of a screening instrument for use in medical set-
tings. J Stud Alcohol. 1995;56(4):423–32.
 9. Braithwaite RS, Bryant KJ. Influence of alcohol consumption on adher-
ence to and toxicity of antiretroviral therapy and survival. Alcohol Res 
Health. 2010;33(3):280–7.
 10. Braithwaite RS, Conigliaro J, McGinnis KA, Maisto SA, Bryant K, Justice 
AC. Adjusting alcohol quantity for mean consumption and intoxication 
threshold improves prediction of nonadherence in HIV patients and HIV-
negative controls. Alcohol Clin Exp Res. 2008;32(9):1645–51. https ://doi.
org/10.1111/j.1530-0277.2008.00732 .x.
 11. Brown JL, DeMartini KS, Sales JM, Swartzendruber AL, DiClemente RJ. 
Interventions to reduce alcohol use among HIV-infected individuals: a 
review and critique of the literature. Curr HIV/AIDS Rep. 2013;10(4):356–
70. https ://doi.org/10.1007/s1190 4-013-0174-8.
Page 10 of 11Madhombiro et al. Addict Sci Clin Pract           (2019) 14:16 
 12. Chandiwana SK, Sebit MB, Latif AS, Gomo E, Acuda SW, Makoni F, Vushe J. 
Alcohol consumption in HIV-I infected persons: a study of immunological 
markers, Harare, Zimbabwe. Cent Afr J Med. 1999;45(11):303–8.
 13. Chinyadza E, Moyo IM, Katsumbe TM, Chisvo D, Mahari M, Cock DE, 
Mbengeranwa OL. Alcohol problems among patients attending five pri-
mary health care clinics in Harare city. Cent Afr J Med. 1993;39(2):26–32.
 14. Collins PY, Musisi S, Frehywot S, Patel V. The core competencies for 
mental, neurological, and substance use disorder care in sub-Saharan 
Africa. Glob Health Action. 2015;8(1):26682. https ://doi.org/10.3402/gha.
v8.26682 .
 15. da Silva CM, Mendoza-Sassi RA, da Mota LD, Nader MM, de Martinez AM. 
Alcohol use disorders among people living with HIV/AIDS in Southern 
Brazil: prevalence, risk factors and biological markers outcomes. BMC 
Infect Dis. 2017;17(1):263. https ://doi.org/10.1186/s1287 9-017-2374-0.
 16. Davis CG, Thake J, Vilhena N. Social desirability biases in self-reported 
alcohol consumption and harms. Addict Behav. 2010;35(4):302–11. https 
://doi.org/10.1016/j.addbe h.2009.11.001.
 17. Edelman EJ, Hansen NB, Cutter CJ, Danton C, Fiellin LE, O’Connor PG, Wil-
liams EC, Maisto SA, Bryant KJ, Fiellin DA. Implementation of integrated 
stepped care for unhealthy alcohol use in HIV clinics. Addict Sci Clin Pract. 
2016;11(1):1. https ://doi.org/10.1186/s1372 2-015-0048-z.
 18. Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Fiellin LE, O’Connor 
PG, Bedimo R, Gibert C, Marconi VC, Rimland D. Corrigendum to “The 
Starting Treatment for Ethanol in Primary care Trials (STEP Trials): protocol 
for three parallel multi-site stepped care effectiveness studies for 
unhealthy alcohol use in HIV-positive patients” [Contemp. Clin. Trials 52 
(2017) 80–90]. Contemp Clin Trials. 2017;60:125. https ://doi.org/10.1016/j.
cct.2017.06.016.
 19. Egbe CO, Dakum PS, Ekong E, Kohrt BA, Minto JG, Ticao CJ. Depression, 
suicidality, and alcohol use disorder among people living with HIV/AIDS 
in Nigeria. BMC Public Health. 2017;17(1):542. https ://doi.org/10.1186/
s1288 9-017-4467-5.
 20. Fairall L, Bachmann MO, Lombard C, Timmerman V, Uebel K, Zwaren-
stein M, Boulle A, Georgeu D, Colvin CJ, Lewin S, Faris G. Task shifting of 
antiretroviral treatment from doctors to primary-care nurses in South 
Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. Lancet. 
2012;380(9845):889–98. https ://doi.org/10.1016/s0140 -6736(12)60730 -2.
 21. Galvan FH, Bing EG, Fleishman JA, London AS, Caetano R, Burnam MA, 
Longshore D, Morton SC, Orlando M, Shapiro M. The prevalence of 
alcohol consumption and heavy drinking among people with HIV in the 
United States: results from the HIV Cost and Services Utilization Study. J 
Stud Alcohol. 2002;63(2):179–86.
 22. Garin O, Ayuso-Mateos JL, Almansa J, Nieto M, Chatterji S, Vilagut G, 
Alonso J, Cieza A, Svetskova O, Burger H, Racca V. Validation of the “World 
Health Organization Disability Assessment Schedule, WHODAS-2” in 
patients with chronic diseases. Health Qual Life Outcomes. 2010;8:51. 
https ://doi.org/10.1186/1477-7525-8-51.
 23. Habtamu K, Alem A, Medhin G, Fekadu A, Dewey M, Prince M, Hanlon C. 
Validation of the World Health Organization Disability Assessment Sched-
ule in people with severe mental disorders in rural Ethiopia. Health Qual 
Life Outcomes. 2017;15(1):64. https ://doi.org/10.1186/s1295 5-017-0647-3.
 24. Heestermans T, Browne JL, Aitken SC, Vervoort SC, Klipstein-Grobusch K. 
Determinants of adherence to antiretroviral therapy among HIV-positive 
adults in sub-Saharan Africa: a systematic review. BMJ Glob Health. 
2016;1(4):e000125. https ://doi.org/10.1136/bmjgh -2016-00012 5.
 25. Hsiung PC, Fang CT, Wu CH, Sheng WH, Chen SC, Wang JD, Yao G. 
Validation of the WHOQOL-HIV BREF among HIV-infected patients in 
Taiwan. AIDS Care. 2011;23(8):1035–42. https ://doi.org/10.1080/09540 
121.2010.54388 1.
 26. Justice AC, McGinnis KA, Tate JP, Braithwaite RS, Bryant KJ, Cook RL, Edel-
man EJ, Fiellin LE, Freiberg MS, Gordon AJ, Kraemer KL. Risk of mortality 
and physiologic injury evident with lower alcohol exposure among 
HIV infected compared with uninfected men. Drug Alcohol Depend. 
2016;161:95–103. https ://doi.org/10.1016/j.druga lcdep .2016.01.017.
 27. Kekwaletswe CT, Morojele NK. Alcohol use, antiretroviral therapy adher-
ence, and preferences regarding an alcohol-focused adherence interven-
tion in patients with human immunodeficiency virus. Patient Prefer 
Adherence. 2014;8:401–13. https ://doi.org/10.2147/PPA.S5554 7.
 28. Lund C, Schneider M, Davies T, Nyatsanza M, Honikman S, Bhana A, Susser 
E. Task sharing of a psychological intervention for maternal depression in 
Khayelitsha, South Africa: study protocol for a randomized controlled trial. 
Trials. 2014;15:457. https ://doi.org/10.1186/1745-6215-15-457.
 29. Madhombiro M, Dube-Marimbe B, Dube M, Chibanda D, Zunza M, 
Rusakaniko S, Stewart D, Seedat S. A cluster randomised controlled trial 
protocol of an adapted intervention for alcohol use disorders in people 
living with HIV and AIDS: impact on alcohol use, general functional abil-
ity, quality of life and adherence to HAART. BMC Psychiatry. 2017;17(1):44. 
https ://doi.org/10.1186/s1288 8-017-1208-3.
 30. McGinnis KA, Fiellin DA, Tate JP, Cook RL, Braithwaite RS, Bryant KJ, 
Edelman EJ, Gordon AJ, Kraemer KL, Maisto SA, Justice AC. Number of 
drinks to “feel a buzz” by HIV status and viral load in men. AIDS Behav. 
2016;20(3):504–11. https ://doi.org/10.1007/s1046 1-015-1053-7.
 31. Medicins Sans Frontieres. Zimbabwe Newsletter (2017).
 32. Megerso A, Garoma S, Eticha T, Workineh T, Daba S, Tarekegn M, Habtamu 
Z. Predictors of loss to follow-up in antiretroviral treatment for adult 
patients in the Oromia region, Ethiopia. HIV AIDS (Auckl). 2016;8:83–92. 
https ://doi.org/10.2147/HIV.S9813 7.
 33. Miller WR, Rollnick S. Motivational interviewing: preparing people to 
change addictive behavior. New York: Guilford Press; 1991.
 34. Moyer A, Finney JW, Swearingen CE, Vergun P. Brief interventions for 
alcohol problems: a meta-analytic review of controlled investigations in 
treatment-seeking and non-treatment-seeking populations. Addiction. 
2002;97(3):279–92.
 35. Mweemba P, Zeller R, Ludwick R, Gosnell D, Michelo C. Validation of the 
World Health Organization Quality of Life HIV instrument in a Zam-
bian sample. J Assoc Nurses AIDS Care. 2011;22(1):53–66. https ://doi.
org/10.1016/j.jana.2010.04.006.
 36. Nadkarni A, Weiss HA, Weobong B, McDaid D, Singla DR, Park AL, Bhat B, 
Katti B, McCambridge J, Murthy P, King M. Sustained effectiveness and 
cost-effectiveness of Counselling for Alcohol Problems, a brief psycholog-
ical treatment for harmful drinking in men, delivered by lay counsellors in 
primary care: 12-month follow-up of a randomised controlled trial. PLoS 
Med. 2017;14(9):e1002386. https ://doi.org/10.1371/journ al.pmed.10023 
86.
 37. Nadkarni A, Weobong B, Weiss HA, McCambridge J, Bhat B, Katti B, 
Murthy P, King M, McDaid D, Park AL, Wilson GT. Counselling for Alcohol 
Problems (CAP), a lay counsellor-delivered brief psychological treatment 
for harmful drinking in men, in primary care in India: a randomised 
controlled trial. Lancet. 2017;389(10065):186–95. https ://doi.org/10.1016/
s0140 -6736(16)31590 -2.
 38. National AIDS Council, Zimbabwe. Follow‐up to the 2011 political decla-
ration on HIV/AIDS: intensifying our efforts to eliminate HIV/AID. Global 
aids response progress report 2016, vol 1, no 1 (2016).
 39. Papas RK, Sidle JE, Gakinya BN, Baliddawa JB, Martino S, Mwaniki MM, 
Songole R, Omolo OE, Kamanda AM, Ayuku DO, Ojwang C. Treatment 
outcomes of a stage 1 cognitive-behavioral trial to reduce alcohol 
use among human immunodeficiency virus-infected out-patients in 
western Kenya. Addiction. 2011;106(12):2156–66. https ://doi.org/10.111
1/j.1360-0443.2011.03518 .x.
 40. Parry CD, Morojele NK, Myers BJ, Kekwaletswe CT, Manda SO, Sorsdahl 
K, Ramjee G, Hahn JA, Rehm J, Shuper PA. Efficacy of an alcohol-focused 
intervention for improving adherence to antiretroviral therapy (ART) and 
HIV treatment outcomes—a randomised controlled trial protocol. BMC 
Infect Dis. 2014;14:500. https ://doi.org/10.1186/1471-2334-14-500.
 41. Parsons JT, Golub SA, Rosof E, Holder C. Motivational interviewing and 
cognitive-behavioral intervention to improve HIV medication adher-
ence among hazardous drinkers: a randomized controlled trial. J Acquir 
Immune Defic Syndr. 2007;46(4):443–50.
 42. Patel V, Araya R, Chatterjee S, Chisholm D, Cohen A, De Silva M, van 
Ommeren M. Treatment and prevention of mental disorders in low-
income and middle-income countries. Lancet. 2007;370(9591):991–1005. 
https ://doi.org/10.1016/S0140 -6736(07)61240 -9.
 43. Perngparn U, Assanangkornchai S, Pilley C, Aramrattana A. Drug and 
alcohol services in middle-income countries. Curr Opin Psychiatry. 
2008;21(3):229–33. https ://doi.org/10.1097/YCO.0b013 e3282 fc1ea 3.
 44. Perula-de Torres LA, Fernandez-Garcia JA, Arias-Vega R, Muriel-Palomino 
M, Marquez-Rebollo E, Ruiz-Moral R. Validity of AUDIT test for detection of 
disorders related with alcohol consumption in women. Med Clin (Barc). 
2005;125(19):727–30.
Page 11 of 11Madhombiro et al. Addict Sci Clin Pract           (2019) 14:16 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 45. Project MATCH Research Group. Matching alcoholism treatments to 
client heterogeneity: treatment main effects and matching effects on 
drinking during treatment. J Stud Alcohol. 1998;59(6):631–9.
 46. Puoti M, Moioli MC, Travi G, Rossotti R. The burden of liver disease in 
human immunodeficiency virus-infected patients. Semin Liver Dis. 
2012;32(2):103–13. https ://doi.org/10.1055/s-0032-13164 73.
 47. Riper H, Andersson G, Hunter SB, de Wit J, Berking M, Cuijpers P. Treat-
ment of comorbid alcohol use disorders and depression with cognitive-
behavioural therapy and motivational interviewing: a meta-analysis. 
Addiction. 2014;109(3):394–406. https ://doi.org/10.1111/add.12441 .
 48. Samet JH, Horton NJ, Meli S, Dukes K, Tripps T, Sullivan L, Freedberg 
KA. A randomized controlled trial to enhance antiretroviral therapy 
adherence in patients with a history of alcohol problems. Antivir Ther. 
2005;10(1):83–93.
 49. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Develop-
ment of the Alcohol Use Disorders Identification Test (AUDIT): WHO 
Collaborative Project on Early Detection of Persons with Harmful Alcohol 
Consumption—II. Addiction. 1993;88(6):791–804.
 50. Sobell MB, Breslin FC, Sobell LC. Project MATCH: the time has come…to 
talk of many things. J Stud Alcohol. 1998;59(1):124–5.
 51. Soboka M, Tesfaye M, Feyissa GT, Hanlon C. Alcohol use disorders and 
associated factors among people living with HIV who are attending 
services in south west Ethiopia. BMC Res Notes. 2014;7:828. https ://doi.
org/10.1186/1756-0500-7-828.
 52. Teixeira C, Dourado Mde L, Santos MP, Brites C. Impact of use of alcohol 
and illicit drugs by AIDS patients on adherence to antiretroviral therapy in 
Bahia, Brazil. AIDS Res Hum Retroviruses. 2013;29(5):799–804. https ://doi.
org/10.1089/AID.2012.0296.
 53. Van Biljon L, Nel P, Roos V. A partial validation of the WHOQOL-OLD in a 
sample of older people in South Africa. Glob Health Action. 2015;8:28209. 
https ://doi.org/10.3402/gha.v8.28209 .
 54. Wandera B, Tumwesigye NM, Nankabirwa JI, Kambugu AD, Mafigiri DK, 
Kapiga S, Sethi AK. Hazardous alcohol consumption is not associated 
with CD4+ T-cell count decline among PLHIV in Kampala Uganda: a 
prospective cohort study. PLoS ONE. 2017;12(6):e0180015. https ://doi.
org/10.1371/journ al.pone.01800 15.
 55. Whetten K, Reif S, Swartz M, Stevens R, Ostermann J, Hanisch L, Eron JJ 
Jr. A brief mental health and substance abuse screener for persons with 
HIV. AIDS Patient Care STDS. 2005;19(2):89–99. https ://doi.org/10.1089/
apc.2005.1.
 56. WHO. WHO Disability Assessment Schedule 2.0 (WHODAS 2.0). http://
www.who.int/class ifica tions /icf/whoda sii/en/ (2017). Accessed Jan 2016.
 57. World Health Organization. mhGAP intervention guide for mental, neu-
rological and substance use disorders in non-specialized health settings. 
http://apps.who.int/iris/bitst ream/10665 /44406 /1/97892 41548 069_eng.
pdf (2010). Accessed Jan 2016.
 58. World Health Organisation. WHOQOL-HIV for quality of life assessment 
among people living with HIV and AIDS: results from the field test. AIDS 
Care. 2004;16(7):882–9. https ://doi.org/10.1080/09540 12041 23312 90194 .
 59. Zule W, Myers B, Carney T, Novak SP, McCormick K, Wechsberg WM. 
Alcohol and drug use outcomes among vulnerable women living with 
HIV: results from the Western Cape Women’s Health CoOp. AIDS Care. 
2014;26(12):1494–9. https ://doi.org/10.1080/09540 121.2014.93376 9.
